Candriam S.C.A. Apellis Pharmaceuticals, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
309Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$524 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$400 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$374 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$330 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$195 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.7B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...